Amicus Therapeutics Inc. (FOLD) announced after the close Monday that it is working with FDA to finalize the clinical protocol for Migalastat and plans to initiate enrollment in 2017, with data expected in 2019. The drug is a treatment for Fabry disease. The FDA indicated that kidney globotriaosylceramide is currently not considered a basis for an accelerated approval under Subpart H.
from RTT - Before the Bell http://ift.tt/2g6fwYa
via IFTTT
No comments:
Post a Comment